Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$1.51M$1.51M+53.8% vs Q1 2017 Net Income-$8.12M-$8.12MN/M vs Q1 2017 EPS Diluted-$0.49-$0.49N/M vs Q1 2017 Operating Income-$8,245,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,530,000N/M Margins · derivedOperating margin-546.0%+98.7 pt vs Q1 2017
Net margin-537.7%+98.5 pt vs Q1 2017
ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end